http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Aegon Completes Sale of Unirobe Meeùs Groep
-
CoolSculpting® Breaks the Ice about Non-Invasive Fat Freezing with Actress Debra Messing
-
Aegon Announces Repurchase of Shares to Neutralize 2016 Final and 2017 Interim Stock Dividends
-
Amgen (AMGN), Allergan (AGN) Confirm FDA Approval of MVASI For Treatment of Five Types of Cancer
-
FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer
-
Aegon Announces Stock Fraction Interim Dividend 2017
-
Amgen (AMGN) & Allergen (AGN) Report Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980
-
Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress
-
Aegon to Divest Its Business in Ireland
-
Aegon to Sell Unirobe Meeùs Groep
-
Amgen (AMGN) & Allergan (AGN) Report U.S. FDA Submission of Biosimilar Biologics License Application For ABP 980
-
Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration
-
Nielsen Reports 2nd Quarter 2017 Results
-
Global economy suffers $53bn natural disaster loss during 1H 2017, according to Aon catastrophe report
-
Ward Group Reveals Its Ward's 50 List of Top Performing Insurance Companies for 2017
-
Aon Declares Quarterly Dividend
-
Amgen (AMGN), Allergan (AGN) to Discuss Data Supporting BLA For ABP 215 with FDA
-
Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)
-
Aon Announces Second Quarter 2017 Earnings Release and Conference Call
-
Flood and convective storm events cost global economy more than $5bn in June, according to Aon catastrophe report
-
Aegon Completes Sale of Majority of US Run-Off Businesses
-
Aegon Announces Stock Fraction Final Dividend 2016
-
Amgen (AMGN) & Allergan (AGN) Reports FDA Advisory Committee Meeting To Review ABP 215 (Biosimilar Candidate To Bevacizumab)
-
Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab
-
Aegon Appoints Global Head of Government and Policy Affairs
-
Aegon to Divest Majority of US Run-Off Businesses
-
Annual Meeting of Shareholders Adopts All Resolutions
-
Allergan's Eyepowerment™ Campaign Releases Survey Revealing the Importance of Eye Language and the Crucial Role it Plays in Our Communications
-
Veeva OpenData Reaches 100th Customer Milestone
-
Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated to Suffer from IBS and CIC to Talk About Bowel Health(1-5)
-
Aegon Publishes Agenda for 2017 Annual General Meeting
-
Aegon Publishes 2016 Annual Report and Review
-
Allergan's New Eyepowerment™ Campaign Urges The Up To 33 Million Americans Suffering from Symptoms of Chronic Dry Eye to Take Action
-
Allergan to Sponsor Alzheimer's Foundation of America '15th Anniversary National Educating America' Tour
-
Aegon Responds to Inaccurate Information
-
S&P 500 ekes out gain while banks drag on Dow
-
Ironwood Pharmaceuticals (IRWD), Allergan (AGN) Gains FDA Approval for 72 mcg Dose of LINZESS
-
U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS® (linaclotide) for Adults with Chronic Idiopathic Constipation
-
Endo Int'l (ENDP) Agrees to Abandon Noncompetitive Pay-for-Delay in Settlement with FTC
-
Ironwood (IRWD), Allergan (AGN) Announce Phase IIb Data for Linaclotide Colonic Release-1 (CR1) in IBS-C; Plan to Advance to Phase III
-
Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide Colonic Release-2 (CR2) for Abdominal Pain in Non-Constipation Subtypes of IBS
-
Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C
-
Aegon Announces Management Changes
-
Aegon Accelerates Execution of Strategy and Increases Expense Savings
-
Amgen (AMGN), Allergan (AGN) Announce Submission of ABP 215 MAA to EMA
-
Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab
-
Aegon to Appoint Matthew Rider as CFO
-
Amgen (AMGN) , Allergan (AGN) Submit Biosimilar BLA for ABP 215
-
Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration
-
Aegon Announces Repurchase of Shares to Neutralize 2016 Interim Stock Dividend

